Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | ADH1A | P07327 | 8/20 | 0.35 |
| ▸ | ADH1C | P00326 | 6/20 | 0.35 |
| ▸ | ADH1B | P00325 | 4/20 | 0.35 |
| ▸ | ADH4 | P08319 | 2/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | ADH7 | P40394 | 2/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL93216 | 0.97 | CA1 (0.39) | CA1CA2ADH1AADH1CADH1B | |
| SCHEMBL2108204 | 0.97 | CA1 (0.39) | CA1CA2ADH1AADH1CADH1B | |
| SCHEMBL8568492 | 0.97 | — | — | |
| SCHEMBL93205 | 0.97 | CA1 (0.39) | CA1CA2ADH1AADH1CADH1B | |
| SCHEMBL2109541 | 0.97 | CA1 (0.39) | CA1CA2ADH1AADH1CADH1B | |
| SCHEMBL9432 | 0.97 | — | — | |
| SCHEMBL2109558 | 0.97 | CA1 (0.39) | CA1CA2ADH1AADH1CADH1B | |
| SCHEMBL2109114 | 0.97 | CA1 (0.39) | CA1CA2ADH1AADH1CADH1B | |
| SCHEMBL93455 | 0.97 | CA1 (0.39) | CA1CA2ADH1AADH1CADH1B | |
| SCHEMBL3627527 | 0.97 | CA1 (0.39) | CA1CA2ADH1AADH1CADH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109651129-A | A kind of 4- isopropyl cyclohexanecarboxylic acid turns structure and separation method along anti-mixture | 浙江清和新材料科技有限公司 | 2019-04-19 | — | — | CN | disclosed |
| CN-1803914-B | Polypropylene resin composition and formed article | SUMITOMO CHEMICAL CO | 2011-08-03 | — | — | CN | disclosed |
| CN-1803914-A | Polypropylene resin composition and formed article | SUMITOMO CHEMICAL CO (JP) | 2006-07-19 | — | — | CN | disclosed |
| US-20040062773-A1 | Compositions for the delivery of antigens | EMISPHERE TECHNOLOGIES INC. | 2004-04-01 | — | — | US | disclosed |
| EP-0784469-B1 | COMPOSITIONS FOR THE DELIVERY OF ANTIGENS | EMISPHERE TECH INC (US) | 2004-03-24 | — | — | EP | disclosed |
| US-6610329-B2 | Using acylated amino acid as carrier | EMISPHERE TECHNOLOGIES INC. | 2003-08-26 | — | — | US | disclosed |
| US-20020001591-A1 | Compositions for the delivery of antigens | EMISPHERE TECHNOLOGIES, INC. | 2002-01-03 | — | — | US | disclosed |
| US-5958457-A | MIXTURES OF ANTIGENS WITH ADJUVANTS AND ACYLATED AMINO ACIDS OR SALTS, POLYMERS OR SULFONATED AMINO ACIDS | EMISPHERE TECHNOLOGIES, INC. (US) | 1999-09-28 | — | — | US | disclosed |
| EP-0784469-A4 | COMPOSITIONS FOR THE DELIVERY OF ANTIGENS | EMISPHERE TECH INC (US) | 1999-03-24 | — | — | EP | disclosed |
| US-5840704-A | INSECTICIDES, MITICIDES, ANTHELMINTICS | PFIZER INC. (US) | 1998-11-24 | — | — | US | disclosed |
| EP-0784469-A1 | COMPOSITIONS FOR THE DELIVERY OF ANTIGENS | Emisphere Technologies, Inc. (US) | 1997-07-23 | — | — | EP | disclosed |
| WO-1996019920-A1 | COMPOSITIONS FOR TREATING NEMATODE INFECTIONS IN TREES | PFIZER PHARMACEUTICALS INC. (JP) | 1996-07-04 | — | — | WO | disclosed |
| WO-1996012474-A1 | COMPOSITIONS FOR THE DELIVERY OF ANTIGENS | EMISPHERE TECHNOLOGIES, INC. (US) | 1996-05-02 | — | — | WO | disclosed |
| US-5451511-A | Biosynthesis, avermectins | PFIZER INC. (US) | 1995-09-19 | — | — | US | disclosed |
| US-5089480-A | ANTIPARASITIC AGENTS | PFIZER INC. (US) | 1992-02-18 | — | — | US | disclosed |
| EP-0214731-A2 | Antiparasitic avermectin and milbemycin derivatives and process for their preparation | Pfizer Limited (GB) | 1987-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020001591-A1 | Compositions for the delivery of antigens | CD47, CD74, LY96 | CA1 111/4885CA2 455/4885ADH1A 4553/4885 |
| US-20040062773-A1 | Compositions for the delivery of antigens | CD47, CD74, LY96 | CA1 111/4885CA2 455/4885ADH1A 4553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.